ZA200906764B - Methods of treating cancer using pyridopyrimidinone inhibitors of P13K alpha - Google Patents

Methods of treating cancer using pyridopyrimidinone inhibitors of P13K alpha

Info

Publication number
ZA200906764B
ZA200906764B ZA200906764A ZA200906764A ZA200906764B ZA 200906764 B ZA200906764 B ZA 200906764B ZA 200906764 A ZA200906764 A ZA 200906764A ZA 200906764 A ZA200906764 A ZA 200906764A ZA 200906764 B ZA200906764 B ZA 200906764B
Authority
ZA
South Africa
Prior art keywords
alpha
methods
treating cancer
pyridopyrimidinone
inhibitors
Prior art date
Application number
ZA200906764A
Other languages
English (en)
Inventor
Peter Lamb
David Matthews
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of ZA200906764B publication Critical patent/ZA200906764B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200906764A 2007-04-10 2009-09-29 Methods of treating cancer using pyridopyrimidinone inhibitors of P13K alpha ZA200906764B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92289907P 2007-04-10 2007-04-10

Publications (1)

Publication Number Publication Date
ZA200906764B true ZA200906764B (en) 2010-08-25

Family

ID=39627802

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200906764A ZA200906764B (en) 2007-04-10 2009-09-29 Methods of treating cancer using pyridopyrimidinone inhibitors of P13K alpha

Country Status (31)

Country Link
US (1) US8513266B2 (cg-RX-API-DMAC7.html)
EP (1) EP2139484B9 (cg-RX-API-DMAC7.html)
JP (3) JP2010523670A (cg-RX-API-DMAC7.html)
KR (1) KR101626435B1 (cg-RX-API-DMAC7.html)
CN (2) CN102727498B (cg-RX-API-DMAC7.html)
AU (1) AU2008236562B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0810206A2 (cg-RX-API-DMAC7.html)
CA (1) CA2683641C (cg-RX-API-DMAC7.html)
CO (1) CO6251254A2 (cg-RX-API-DMAC7.html)
CR (1) CR11100A (cg-RX-API-DMAC7.html)
DK (1) DK2139484T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2009000243A (cg-RX-API-DMAC7.html)
EA (1) EA020022B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP099724A (cg-RX-API-DMAC7.html)
ES (1) ES2430614T3 (cg-RX-API-DMAC7.html)
HN (1) HN2009003002A (cg-RX-API-DMAC7.html)
HR (1) HRP20130688T1 (cg-RX-API-DMAC7.html)
IL (1) IL201284A (cg-RX-API-DMAC7.html)
MA (1) MA31358B1 (cg-RX-API-DMAC7.html)
ME (1) ME00936B (cg-RX-API-DMAC7.html)
MX (1) MX2009010930A (cg-RX-API-DMAC7.html)
MY (1) MY150697A (cg-RX-API-DMAC7.html)
NZ (1) NZ580110A (cg-RX-API-DMAC7.html)
PL (1) PL2139484T3 (cg-RX-API-DMAC7.html)
PT (1) PT2139484E (cg-RX-API-DMAC7.html)
RS (1) RS52939B (cg-RX-API-DMAC7.html)
SI (1) SI2139484T1 (cg-RX-API-DMAC7.html)
TN (1) TN2009000400A1 (cg-RX-API-DMAC7.html)
UA (1) UA100979C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008124161A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200906764B (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
HRP20130902T1 (hr) * 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
NZ608667A (en) * 2005-10-07 2014-08-29 Exelixis Inc N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
DK2139484T3 (da) 2007-04-10 2013-10-21 Exelixis Inc Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa
RS53020B (sr) * 2007-04-11 2014-04-30 Exelixis Inc. Kombinovane terapije koje sadrže hinoksalin inhibitor pi3k-alfa za upotrebu u lečenju kancera
CA2734489C (en) * 2008-08-20 2016-11-08 Southern Research Institute Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734487A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022126A1 (en) 2008-08-20 2010-02-25 Schering Corporation Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5731976B2 (ja) 2008-08-20 2015-06-10 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 置換ピリジン誘導体および置換ピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
WO2011100319A1 (en) 2010-02-09 2011-08-18 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
US20130156768A1 (en) * 2010-08-26 2013-06-20 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
CA2812089C (en) 2010-09-14 2020-02-18 Exelixis Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
WO2012065019A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha
US9441013B2 (en) * 2011-05-17 2016-09-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
US20140298493A1 (en) * 2011-07-28 2014-10-02 Somasekar Seshagiri PIK3CA H1047R Knock-In Non-Human Animal Breast Cancer Model
WO2013056067A1 (en) * 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
KR20140096083A (ko) 2011-11-01 2014-08-04 엑셀리시스, 인코포레이티드 림프증식성 악성종양의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제로서 ｎ­（3­｛［（3­｛［2­클로로­5­（메톡시）페닐］아미노｝퀴녹살린­2­일）아미노］설포닐｝페닐）­2­메틸알라닌아미드
JP6126615B2 (ja) * 2011-11-11 2017-05-10 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
US20150010545A1 (en) * 2011-12-27 2015-01-08 Kadmon Corporation, Llc Methods for treatment of breast cancer nonresponsive to trastuzumab
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
US8980259B2 (en) * 2012-07-20 2015-03-17 Novartis Ag Combination therapy
AU2013299841B8 (en) 2012-08-07 2017-01-05 Array Biopharma Inc. Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
JP7085985B2 (ja) 2016-03-04 2022-06-17 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
CU24522B1 (es) * 2016-08-15 2021-06-08 Pfizer PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS
JP7027699B2 (ja) * 2017-05-09 2022-03-02 住友ゴム工業株式会社 タイヤトレッドおよびタイヤ
MX2020008015A (es) 2018-01-31 2020-10-16 Deciphera Pharmaceuticals Llc Terapia de combinación para el tratamiento de la mastocitosis.
EP3746059A1 (en) 2018-01-31 2020-12-09 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
KR102473372B1 (ko) 2018-03-19 2022-12-05 다이호야쿠힌고교 가부시키가이샤 알킬황산나트륨을 포함하는 의약 조성물
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
US12486246B2 (en) 2019-12-10 2025-12-02 The Trustees Of Indiana University Replication protein A (RPA)-DNA interaction inhibitors
KR20250057151A (ko) 2019-12-30 2025-04-28 데시페라 파마슈티칼스, 엘엘씨 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
KR102195221B1 (ko) 2019-12-31 2020-12-24 서울대학교산학협력단 포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물
CN111358952B (zh) * 2020-04-15 2022-03-15 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种抗肿瘤药物组合物及其制剂和应用
CN118678960A (zh) * 2021-11-18 2024-09-20 安可诺瓦治疗公司 用于治疗癌症的方法和组合物
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
ES2400339T3 (es) * 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
EP1718645A1 (en) * 2004-02-18 2006-11-08 Warner-Lambert Company LLC 2-(pyridin-3-ylamino)-pyrido 2,3-d pyrimidin-7-ones
US20080255162A1 (en) * 2004-05-04 2008-10-16 Warner-Lambert Company Llc Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents
JP5216958B2 (ja) * 2005-07-06 2013-06-19 株式会社三和技術総合研究所 漏洩電流検出装置及び漏洩電流検出方法
HRP20130902T1 (hr) * 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
NZ608667A (en) * 2005-10-07 2014-08-29 Exelixis Inc N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
MY146420A (en) * 2006-09-15 2012-08-15 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
DK2139484T3 (da) 2007-04-10 2013-10-21 Exelixis Inc Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa
RS53020B (sr) * 2007-04-11 2014-04-30 Exelixis Inc. Kombinovane terapije koje sadrže hinoksalin inhibitor pi3k-alfa za upotrebu u lečenju kancera
AU2008239655B2 (en) 2007-04-11 2013-06-20 Exelixis, Inc. Pyrido (2, 3-d) pyrimidin-7-one compounds as inhibitors of PI3k-alpha for the treatment of cancer
AU2008239596B2 (en) 2007-04-11 2013-08-15 Exelixis, Inc. Pyrido [2,3-D] pyrimidin-7-one compounds as inhibitors of PI3K-alpha for the treatment of cancer
TW201018685A (en) * 2008-09-30 2010-05-16 Exelixis Inc Pyridopyrimidinone inhibitors of PI3Kα and mTOR

Also Published As

Publication number Publication date
PL2139484T3 (pl) 2013-12-31
HRP20130688T1 (en) 2013-09-30
MY150697A (en) 2014-02-28
BRPI0810206A2 (pt) 2014-10-21
EP2139484B8 (en) 2013-08-21
CO6251254A2 (es) 2011-02-21
CA2683641C (en) 2016-08-16
KR20100016354A (ko) 2010-02-12
ECSP099724A (es) 2010-03-31
US20100209420A1 (en) 2010-08-19
DOP2009000243A (es) 2010-10-31
DK2139484T3 (da) 2013-10-21
ME00936B (me) 2012-06-20
EP2139484B1 (en) 2013-07-17
IL201284A0 (en) 2010-05-31
WO2008124161A1 (en) 2008-10-16
NZ580110A (en) 2012-06-29
EA020022B1 (ru) 2014-08-29
ES2430614T3 (es) 2013-11-21
KR101626435B1 (ko) 2016-06-01
US8513266B2 (en) 2013-08-20
PT2139484E (pt) 2013-10-31
CN102727498A (zh) 2012-10-17
EP2139484A1 (en) 2010-01-06
UA100979C2 (ru) 2013-02-25
EP2139484B9 (en) 2014-06-11
CN101715345A (zh) 2010-05-26
HN2009003002A (es) 2014-03-24
MA31358B1 (fr) 2010-05-03
TN2009000400A1 (en) 2010-12-31
EA200970932A1 (ru) 2010-04-30
JP2014139217A (ja) 2014-07-31
IL201284A (en) 2016-06-30
CR11100A (es) 2010-01-19
HK1139863A1 (en) 2010-09-30
AU2008236562B2 (en) 2013-11-07
SI2139484T1 (sl) 2013-10-30
AU2008236562A1 (en) 2008-10-16
CN102727498B (zh) 2016-08-03
RS52939B (sr) 2014-02-28
JP2014034576A (ja) 2014-02-24
MX2009010930A (es) 2010-01-20
JP2010523670A (ja) 2010-07-15
CA2683641A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
ZA200906764B (en) Methods of treating cancer using pyridopyrimidinone inhibitors of P13K alpha
IL257681A (en) Methods and compositions for the treatment of cancer
EP2211854A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
IL218987A0 (en) Methods and compositions for treating cancer
PT2365802T (pt) Microcápsulas de rapamicina e utilização para o tratamento de cancro
EP2318406A4 (en) THIOSEMICARBAZONHERMAL COMPOUNDS AND CANCER TREATMENT PROCEDURES
IL217558A0 (en) Benzoxazepin p13k inhibitor compounds and methods of use
IL197315A0 (en) Treatment of cancer
ZA201006988B (en) Method and compositions for treatment of cancer
PL2340042T3 (pl) Sposoby i kompozycje do leczenia raka
IL196208A0 (en) Methods for cancer treatment using tak1 inhibitors
IL199689A0 (en) Compounds and method for treatment of cancer
EP2176406A4 (en) COMPOSITIONS AND METHOD FOR CANCER TREATMENT
PL2187967T3 (pl) Sposoby i kompozycje do leczenia raka
EP2225226A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER
EP2086560A4 (en) METHODS OF TREATING EPIPHORA
IL218230A0 (en) Method of treating cancer
LT2519231T (lt) Proteosomų inhibitoriai vėžio gydymui
IL196361A0 (en) Combination methods of treating cancer
ZA200904158B (en) Methods of cancer treatment with IGF1R inhibitors
GB0600903D0 (en) Treatment of cancer
IL211752A0 (en) Antibody combinations and use of same for treating cancer
HK1129239A (en) Methods for cancer treatment using tak1 inhibitors
GB0622581D0 (en) Treatment of cancer
GB0712513D0 (en) Treatment of cancer